DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Egg Allergy - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Egg Allergy - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical...
January 2022
60 pages
Emesis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Emesis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and...
January 2022
60 pages
Emphysema - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Emphysema - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical a...
January 2022
60 pages
Encephalomyelitis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Encephalomyelitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hist...
January 2022
60 pages
Endocarditis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Endocarditis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historica...
January 2022
60 pages
Enoyl-ACP reductase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 2-3 Business Days DelveInsight’s, “Enoyl-ACP reductase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 2+ compani...
January 2022
60 pages
Eosinophilic Disorder - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Eosinophilic Disorder - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
Eosinophilic Esophagitis - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Eosinophilic Esophagitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the diseas...
January 2022
60 pages
Ependymoma - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Ependymoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical...
January 2022
60 pages
Epidemic Parotitis - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Epidemic Parotitis - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, his...
January 2022
60 pages
Epidermolysis Bullosa (EB) - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Epidermolysis Bullosa (EB) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the dise...
January 2022
60 pages
Epidermolysis Bullosa - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Epidermolysis Bullosa - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
Epithelioid Sarcoma - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Epithelioid Sarcoma - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, hi...
January 2022
60 pages
Epoetin alfa– Biosimilar Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “Epoetin alfa– Biosimilar 2022,” report provides comprehensive insights about 15+ companies and 20+ marketed and pipeline...
January 2022
60 pages
Epstein Barr virus (EBV) - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Epstein Barr virus (EBV) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the diseas...
January 2022
60 pages
ERBB 2 receptor antagonists - Pipeline Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 2-3 business days DelveInsight’s, “ERBB 2 receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies...
January 2022
80 pages
